Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Roche

14 shared events · Importance 5 · Last updated Sep 22, 2026

Importance
5
Shared Events
14
Actions
1
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
100
Regulatory
United States — Food and Drug Administration: The FDA granted clearance to the Elecsys pTau217 blood test, a regulatory action that enables U.S. marketing and use of the test.
Roche: Roche developed the test and received FDA clearance, expanding its Alzheimer's diagnostic portfolio and potentially increasing revenue from test sales and analyzer usage.
Aug 24, 2026 · 7 articles
92
Regulatory
United States — Food and Drug Administration: The FDA granted Priority Review and will decide on approval by 10 January 2027, making it the key regulatory gatekeeper for the drug's U.S. launch.
Roche: Roche is the sponsor of the Enspryng MOGAD filing and stands to gain a first-in-class label expansion if approved, reinforcing its neurology portfolio and offering incremental revenue from 2027.
Sep 09, 2026 · 6 articles
89
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration>>> granted Priority Review for Roche>>>'s Atezolizumab, indicating a potential new treatment option for colon cancer patients.
Roche: Roche's supplemental Biologics License Application for Atezolizumab has been accepted by the United States — Food and Drug Administration>>> for Priority Review, potentially leading to a new standard of care for stage III colon cancer and boosting its market position.
Jun 11, 2026 · 6 articles
79
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration>>> accepted F. Hoffmann-La Roche — Genentech>>>'s New Drug Application for giredestrant under Priority Review, setting a decision date for approval by November 30, 2026.
Roche: As the parent company of F. Hoffmann-La Roche — Genentech>>>, Roche>>> benefits from the positive developments regarding giredestrant's regulatory progress and its potential market impact.
Jun 02, 2026 · 6 articles
63
Business
United States — Food and Drug Administration: The FDA is investigating the outbreak and is referenced, but the new tests are research-use-only and not subject to FDA approval.
Roche: Roche is the main actor, launching new PCR tests to expand its cyclospora portfolio, reinforcing its position in infectious disease diagnostics and potentially boosting sales.
Aug 06, 2026 · 6 articles
57
Business
United States — Food and Drug Administration: The US FDA provides supportive regulatory frameworks that facilitate product approvals and market growth in North America.
Roche: Roche is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
49
Tech
United States — Food and Drug Administration: The FDA is the regulatory authority that must approve the vaccine. Approval could come as soon as 2027, but the agency's review process and potential political interference from the administration could affect the timeline.
Roche: Roche is partnering with BioNTech on a similar cancer vaccine. The positive trial results could accelerate interest and investment in their program.
Aug 19, 2026 · 126 articles
49
Business
United States — Food and Drug Administration: The FDA granted IND clearance for HM17321 in November 2025, enabling the Phase 1 trial. Its regulatory role is crucial for the drug's development.
Roche: As the parent of F. Hoffmann-La Roche — Genentech, Roche strengthens its cardiometabolic portfolio, aligning with its strategy to address obesity and related conditions.
Jul 20, 2026 · 7 articles
45
Regulatory
United States — Food and Drug Administration: The FDA previously approved Signatera as a companion diagnostic for adjuvant Tecentriq, providing a regulatory precedent that supports the Japan submission.
Roche: Roche, parent of F. Hoffmann-La Roche — Genentech, stands to benefit from expanded use of Tecentriq in MIBC, potentially increasing drug sales.
Aug 05, 2026 · 7 articles
42
Regulatory
United States — Food and Drug Administration: The FDA granted approval for the phase II trial, acting as the regulatory authority enabling the clinical development of ziresovir in the U.S.
Roche: Roche is a strategic partner of ArkBio, and the advancement of ziresovir could strengthen their collaboration and potential commercial interests.
Jul 20, 2026 · 6 articles
32
Regulatory
United States — Food and Drug Administration: The FDA previously approved Signatera as a companion diagnostic for adjuvant atezolizumab in MIBC, a precedent referenced in the Japanese approval.
Roche: Roche, as parent of F. Hoffmann-La Roche — Genentech, indirectly benefits from expanded companion diagnostic use of atezolizumab in Japan.
Sep 22, 2026 · 6 articles
21
Tech
United States — Food and Drug Administration: The FDA granted accelerated approval to Etcamah a week before the trial failure, a decision now under scrutiny as confirmatory data fell short of the primary endpoint.
Roche: Roche's similar drug combination failed to significantly slow disease progression in March, a prior event that analysts cited as context making the AstraZeneca setback well anticipated.
Sep 11, 2026 · 6 articles
14
Business
United States — Food and Drug Administration: The FDA granted priority review to del-zota in DMD44 and is set to meet with Novartis on next steps for del-brax in FSHD, keeping the agency central to the remaining AOC pipeline.
Roche: Roche is referenced as a Swiss rival whose total shareholder returns under the same period were lower than Novartis', providing context for investor patience with management.
Sep 08, 2026 · 21 articles
0
Regulatory
Jun 12, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Roche interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.